To the best of our knowledge, this is the first work that has analyzed the effect of the CRISPR-mediated knockout of NKG2A, CD96, CBLB, and A2AR in expanded NK cells against the U937 CD19/Luc (AML) and Nalm-6 GFP/Luc (B-ALL) cell lines. The gene discussed is CD96; the disease is acute myeloid leukemia.